Findings are from the multicenter, prospective, Phase 3 STAMPEDE trial “Our findings suggest that the Decipher Prostate test may provide an important new tool to help guide treatment decisions for the ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic ...
Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...
Leveraging Electronic Health Record Tools and Social Work to Improve Advance Care Planning Documentation in Older Adults With Cancer Their investigation was a study imbedded in a randomized trial ...
SAN FRANCISCO — A genomic test can identify patients with recurrent prostate cancer who are most likely to benefit from adding hormone therapy to secondary radiotherapy, according to findings ...
Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in Cell show that the Decipher Prostate Genomic ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results